37 Results for "

bifunctional inhibitor

" in MedChemExpress (MCE) Product Catalog:
Products (37)

37 Results for "bifunctional inhibitor" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-153341
CAS No.: 2882165-79-7
Purity:  99.41%
Synonyms: CFT1946
Target:  

PROTACs Raf

Research Areas:  

Cancer

Tagarafdeg (CFT1946) is an orally active, blood-brain barrier-penetrant, and selective bifunctional BiDAC degrader of the BRAF V600E/K mutant protein, with a DC50 of 14 nM in A375 cells. Tagarafdeg mediates the ubiquitination and proteasomal degradation of BRAF mutant proteins. Tagarafdeg inhibits tumor progression in multiple models of BRAF V600E-mutant intracranial tumors, melanoma, and colorectal cancer. Tagarafdeg is applicable to tumor-related research .
loading...
    loading...
Cat. No.: HY-153552A
CAS No.: 2990021-73-1
Purity:  99.89%
Target:  

FAP

Research Areas:  

Cancer

NH2-UAMC1110 TFA is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 TFA is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose effect, and has been used in tumor diagnosis. NH2-UAMC1110 TFA structurally incorporates an active amino group, allowing it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.) to synthesize molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 TFA specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling-related processes. Its key activity is high targeting and high affinity, and its core function is to act as a targeting module coupled with bifunctional chelators (such as DOTA, DATA5m). NH2-UAMC1110 TFA can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
loading...
    loading...
Cat. No.: HY-153552
CAS No.: 2758337-19-6
Target:  

FAP

Research Areas:  

Cancer

NH2-UAMC1110 is an aminobutoxy derivative of the fibroblast activation protein (FAP) inhibitor UAMC1110 (HY-100684), and is a precursor compound for the synthesis of FAP inhibitor probes, not directly used in bioactivity experiments. For example, NH2-UAMC1110 is involved in the synthesis of the radiotracer FAPI-QS, which exhibits high tumor selectivity and high dose-response, and has been used for tumor diagnosis. NH2-UAMC1110 introduces an active amino group into its structure, enabling it to form covalent bonds with various molecules (such as DOTA, DATA5m, radionuclide chelators, etc.), thereby synthesizing molecular imaging probes or targeted compounds with the ability to target FAP. NH2-UAMC1110 specifically binds to the FAP active site, inhibiting its proline-selective serine protease activity (including dipeptidyl peptidase and endopeptidase activity), blocking FAP-mediated tissue remodeling processes. Its key activity is high targeting and high affinity, and its core function is to be coupled with bifunctional chelators (such as DOTA, DATA5m) as a targeting module. NH2-UAMC1110 can be applied to diagnostic imaging studies of tumors expressing FAP (such as colorectal cancer, pancreatic cancer, etc.), and also provides molecular tools for targeted research of FAP-related diseases with high FAP expression, such as fibrosis and arthritis .
loading...
    loading...
Cat. No.: HY-144258
CAS No.: 2499965-12-5
Purity:  99.85%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .
loading...
    loading...
Cat. No.: HY-171860
CAS No.: 3066894-28-5
Target:  

PROTACs HIV

Research Areas:  

Infection Cancer

FC-14369 is a PROTAC degrader targeting the HIV-1 Nef protein, with a DC50 value of 160 nM. Through its bifunctional structure, FC-14369 binds to Nef and the Cereblon E3 ubiquitin ligase, induces Nef ubiquitination and proteasomal degradation, restores the expression of cell-surface CD4 and MHC-I, and inhibits HIV-1 replication. FC-14369 can be used in research on HIV infection and AIDS. FC-14369 is applicable to studies related to HIV-1 infection .
loading...
    loading...
Cat. No.: HY-162809
CAS No.: 2251130-41-1
Target:  

Ras

Research Areas:  

Cancer

XMU-MP-9 is a bifunctional compound that binds to the C2 domain of Nedd4-1 and the allosteric site of K-Ras. XMU-MP-9 enhances the interaction between Nedd4-1 and K-Ras, induces conformational changes in the Nedd4-1/K-Ras complex, promotes the ubiquitination and degradation of multiple K-Ras mutants, and inhibits the proliferation of cells carrying K-Ras mutants. XMU-MP-9 can be used for the study of colon, lung and pancreatic cancer .
loading...
    loading...
Cat. No.: HY-159493
Research Areas:  

Cancer

BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC50=23 nM), exhibits selective toxicity against p53 mutant cancer cells .
loading...
    loading...
Cat. No.: HY-164552
CAS No.: 920915-26-0
Target:  

Androgen Receptor

Research Areas:  

Cancer

ZNU-IMB-Z15 is a bifunctional, selective androgen receptor (AR) antagonist and degrader. ZNU-IMB-Z15 directly binds to the ligand-binding domain (LBD) and transactivation function 1 (AF1) of AR, with an IC50 of 63.3 nM for competitive binding to AR LBD and a KD of 0.93 μM for AR AF1. ZNU-IMB-Z15 inhibits AR transcriptional activity and promotes the degradation of AR and ARV7 via the ubiquitin-proteasome pathway. ZNU-IMB-Z15 can be used for the research of castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-29244
CAS No.: 67095-44-7
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

ATIC-IN-2 (Compound 1) is a competitive inhibitor for the bifunctional enzyme AICAR Tfase/IMPCH (ATIC), that binds to inosine monophosphate cyclohydrolase (IMPCH) with a Ki of 0.13 μM .
loading...
    loading...
Cat. No.: HY-118998
CAS No.: 1603845-42-6
Target:  

HyT EGFR ERK Akt

Research Areas:  

Cancer

TX2-121-1 is a bifunctional hydrophobic tag Her3 degrader and also a Her3 inhibitor with an IC50 of 49 nM. TX2-121-1 covalently binds to Cys721 of Her3, induces Her3 degradation via the Hsp70/Hsp90-assisted proteasomal pathway, interferes with the heterodimerization of Her3 with Her2/c-Met, and attenuates downstream Erk/Akt signaling, thereby inhibiting Her3-dependent cancer cell growth. TX2-121-1 can be used for the research of non-small cell lung cancer, ovarian cancer and Her3-driven breast cancer .
loading...
    loading...
Cat. No.: HY-148527
CAS No.: 1347232-69-2
Synonyms: AZD8999
LAS190792 is a bifunctional muscarinic acetylcholine receptor (mAChR) antagonist and β2-adrenergic receptor agonist. LAS190792 has a pIC50 of 8.8 against human M3 muscarinic receptor and a pIC50 of 9.1 against human β2-adrenergic receptor. LAS190792 exhibits vasodilatory and anti-inflammatory activities, and induces sustained bronchodilation in dogs. LAS190792 inhibits the release of IL-8, MMP9, IL-1β and GM-CSF from lipopolysaccharide-stimulated neutrophils. LAS190792 can be used in research related to respiratory system diseases .
loading...
    loading...
Cat. No.: HY-159570
CAS No.: 2710221-08-0
XD2-149 is a ZFP91 PROTAC degrader with DC50 values of 0.08 μM and 0.06 μM, respectively. ZFP91 is a bifunctional nuclear protein with both transcription factor and E3 ubiquitin ligase activities, and is classified as an oncogenic non-canonical NF-κB pathway regulator in tumor and immune regulation. XD2-149 induces proteasome-dependent degradation of the E3 ubiquitin-protein ligase ZFP91. XD2-149 inhibits the STAT3 signaling pathway in pancreatic cancer cells and induces NQO1-dependent cell death independent of ZFP91 degradation. XD2-149 can be used for the research of pancreatic cancer .
loading...
    loading...
Cat. No.: HY-164575
CAS No.: 1630114-57-6
Research Areas:  

Cancer

NH2-NODAGA is an amino-modified NODAGA-type bifunctional chelator, specifically designed for amidation coupling with targeting ligands via squaric acid (SA), followed by coordination with radionuclides (e.g., 68Ga, 177Lu). NH2-NODAGA can be coupled with diethyl squarate to form a PSMA inhibitor conjugate, which is used in prostate cancer research .
loading...
    loading...
Cat. No.: HY-158685
CAS No.: 2360561-90-4
Target:  

MDM-2/p53

Research Areas:  

Cancer

RG7112D is a potent MDM2 inhibitor with IC50s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC50=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .
loading...
    loading...
Cat. No.: HY-136952
CAS No.: 1822331-55-4
p-SCN-Bn-HOPO is a bifunctional chelator that forms stable octadentate complexes with Zr (IV) and 89Zr 4+ via four 1,2-hydroxypyridone groups. p-SCN-Bn-HOPO conjugates with antibodies through the formation of thiourea bonds with lysine residues, and enables efficient 89Zr radiolabeling under mild conditions. p-SCN-Bn-HOPO inhibits bone uptake of free radiometals, stabilizes radiometal-antibody conjugates, and achieves PET imaging with low background and enhanced tumor-to-organ contrast. p-SCN-Bn-HOPO can be used in breast cancer-related research .
loading...
    loading...
Cat. No.: HY-120281
CAS No.: 2126038-25-1
Target:  

MEK PI3K Akt Apoptosis Caspase

Research Areas:  

Cancer

ST-168 is an orally active MEK/PI3K inhibitor with an IC50 of 182 nM against MEK1 and IC50 values ​​of 69.2, 41.7, 1482 and 2293 nM against PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ respectively. ST-168 completely inhibits the phosphorylation of ERK1/2 and AKT and induces cancer cell death in a 3D tumor sphere model. ST-168 demonstrates significant antitumor effects in the A375 melanoma mouse model. ST-168 improves the ocular toxicity profile of MEK inhibitors, showing lower caspase activation levels, indicating reduced apoptosis induction. ST-168 can be used in melanoma research .
loading...
    loading...
Cat. No.: HY-172396
Target:  

PD-1/PD-L1 VISTA

Research Areas:  

Cancer

PD-L1/VISTA-IN-2 (Compound S8) is an orally active bifunctional PD-L1/VISTA inhibitor with an IC50 of 1.4 μM for PD-L1 and a KD of 2.1 μM for VISTA. PD-L1/VISTA-IN-2 can activate the tumor immune microenvironment and exert anti-cancer effects .
loading...
    loading...
Cat. No.: HY-170598
CAS No.: 3119106-17-8
Research Areas:  

Infection

HP211206 is a bifunctional CRBN-recruiting SARS-CoV-2 M pro PROTAC degrader with a CRBN IC50 of 3.2 μM and a SARS-CoV-2 M pro DC50 of 621 nM. HP211206 recruits E3 ubiquitin ligase CRBN to drive ubiquitination and proteasomal degradation of wild-type SARS-CoV-2 M pro and E166 mutant while inhibiting M pro enzymatic activity, exhibits no cytotoxicity against normal mammalian cells at tested concentrations, and can be used for the study of COVID-19 and SARS-CoV-2 infection
loading...
    loading...
Cat. No.: HY-179077
CAS No.: 2416130-49-7
Research Areas:  

Cancer

PROTAC BTK/IKZF1/3 Degrader-1 is an orally active PROTAC-IMiD bifunctional protein degrader that selectively degrades BTK, IKZF1 and IKZF3. PROTAC BTK/IKZF1/3 Degrader-1 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, mediating ubiquitination and proteasome-dependent degradation of target proteins, with no obvious degrading effect on GSPT1. PROTAC BTK/IKZF1/3 Degrader-1 inhibits cancer cell proliferation, induces cancer cell apoptosis, and suppresses tumor growth. PROTAC BTK/IKZF1/3 Degrader-1 can be used for the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-179560
Research Areas:  

Cancer

PMV6-PEG4-BI2536 is an RIPTAC-like bifunctional molecule that promotes the formation of the p53 Y220C-PLK1 ternary complex (EC50 = 1.4 μM). PMV6-PEG4-BI2536 causes PLK1 mislocalization and inhibits PLK1 activity, inducing G2/M phase arrest and apoptosis in p53 Y220C-mutant cells, while sparing cells with wild-type TP53. PMV6-PEG4-BI2536 can be used in research on uterine, gastric, pancreatic, prostate, and breast cancers harboring the p53 Y220C mutation. PMV6-PEG4-BI2536 is composed of PMV6 (a p53 Y220C mutant-binding ligand), PEG4 (a linker), and BI2536 (HY-159493) (a PLK inhibitor) .
loading...
    loading...